Stockreport

UroGen Delivers Updated Complete Response (CR) and Durability Data from the UGN-101 Phase 3 OLYMPUS Trial

UroGen Pharma Ltd. - Ordinary Shares  (URGN) 
Last urogen pharma ltd. - ordinary shares earnings: 3/2 08:00 am Check Earnings Report
US:NASDAQ Investor Relations: investors.urogen.com
PDF Complete Response (CR) Rate Consistent at 59 Percent Six-month Durability Strong with 89 Percent of Evaluable Patients Remaining in CR [Read more]